The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: Mg Oxide
- Registration Number
- NCT01854437
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.
Exclusion Criteria
Mg level >3 mg/dl
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Mg Oxide Mg Oxide Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
- Primary Outcome Measures
Name Time Method plasma phosphate level 4 week
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shiraz University Hemodialysis Center
🇮🇷Shiraz, Fars, Iran, Islamic Republic of